This video recording was organised and funded by Eli Lilly.
Alzheimer’s disease (AD) gradually affects cognition, independence, and quality of life, placing a significant burden on patients, care partners, and healthcare systems. Early and accurate diagnosis is clinically important, particularly as new treatments are most effective when symptoms are mild.
Key Topics:
- Understand why early diagnosis is critical and the narrow window of opportunity for intervention
- Explore how amyloid-targeted therapies are changing the assessment and diagnosis of AD
- Learn how blood-based biomarkers could support earlier identification and faster referral pathways
- Discover why listening to patients with subtle cognitive concerns is increasingly important in clinical practice
Timestamps:
00:37 – Federica Agosta
01:07 – Emer MacSweeney
01:37 – The role of biomarkers in diagnosis
02:27 – Primary care and early referral
03:37 – Blood-based biomarker tests
04:24 – Recent innovations in AD
Speakers:
Federica Agosta1
1. San Raffaele Scientific Institute, Milan, Italy
Disclosures: Honoraria from: Biogen Idec, Bristol Myers Squibb, Eisai, Eli Lilly, GE Healthcare, Neuraxpharm, and Roche.
Research support: Italian Ministry of Health, the Italian Ministry of University and Research, AriSLA (Fondazione Italiana di Ricerca per la SLA), the European Research Council (ERC), the EU Joint Programme – Neurodegenerative Disease Research (JPND), and Foundation Research on Alzheimer Disease (France).
Emer MacSweeny2
2. Consultant Interventional Neuroradiologist, Co-Founder & CEO of Re:Cognition Head
Disclosure: Speaking engagements: Eli Lilly, Eisai.
Principal Investigator for Clinical Trials: AbbVie, Acadia Pharmaceuticals, AC Immune, Axovant, Biogen, Bioproject, Bristol Myers Squibb, Eisai, Eli Lilly, GAP (Global Alzheimer’s Platform), Immune Bio, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Servier, Suven Life, Theravance, Janssen, TauRx, UCB.
